A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter System

Study Overview
=================
Brief Summary
-----------------
The Bard® Denali™ Retrievable Inferior Vena Cava (IVC) study is a prospective, multi-center study which is intended to provide evidence of safety of the placement and retrieval of the Bard® Denali™ Retrievable Inferior Vena Cava Filter in subjects requiring IVC interruption to protect against pulmonary embolism (PE).

Official Title
-----------------
A Prospective, Multi-Center Study of the Bard® Denali™ Retrievable Inferior Vena Cava Filter

Conditions
-----------------
Pulmonary Embolism

Intervention / Treatment
-----------------
* Device: Denali inferior vena cava filter


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The subject or their legally authorized representative demonstrates understanding of the nature of the study and voluntarily provides written informed consent prior to any data collection or study procedures. The subject is ≥ 21 years old, must be either a male or non-pregnant female with an expected lifespan sufficient to allow for completion of all study procedures. A negative pregnancy test result (urine or blood) is required prior to implant. If an enrolled female becomes pregnant prior to study completion, participation in the study will be terminated. Based on Investigator judgment, the subject is at increased risk of PE requiring vena caval interruption. Note: Subjects diagnosed with acute DVT and/or PE must have objective confirmation based on imaging evidence of at least one of those diagnoses. Patients without PE or venous thromboembolic disease (VTED) who are at risk of PE may be enrolled in this trial. However, enrollment of these patients will be limited to a maximum of 40% of the total sample size. Based on Investigator's judgment, the subject has patent venous anatomy suitable for femoral or jugular/subclavian access for filter placement (e.g. no excessive tortuosity). The IVC is ≤ 28 mm in diameter at the intended implantation site based on radiographic imaging evidence. Based on Investigator's judgment, the filter can be safely placed such that the position of the filter tip is 1 cm below the lowest renal vein. Retrieval of the filter is expected within 180 days post placement. At the six month follow up, if the Investigator determines that the filter continues to be clinically indicated, the filter may be left in place until the risk of PE has passed or left in permanently. All patients not having their filter retrieved at six months will continue be followed to 24 months or one month post filter retrieval, whichever comes first. The subject has patent venous anatomy suitable for jugular access for retrieval of the filter based on imaging evidence within 48 hours prior to the filter placement procedure. Imaging mode will be at physician's discretion. The subject is willing to comply with the protocol requirements and specified follow-up evaluations. Exclusion Criteria: The subject has a previously implanted filter in the IVC or superior vena cava (SVC). The subject has a duplicated or left-sided IVC. The subject has a severe spinal deformity that would impede access to the IVC for the filter placement or filter retrieval procedures. The subject has a serum creatinine ≥ 2 mg/dl (and not on dialysis) within seven days of study enrollment. Patients on dialysis are allowed to participate in this trial. The subject has a known uncorrectable bleeding diathesis or active coagulopathy. The subject has a life expectancy of < 25 months. The subject has a known allergy or sensitivity to nickel or titanium. The subject has a known allergy or sensitivity to iodinated contrast media, which cannot be adequately pre-medicated. NOTE: Alternative contrast agents are not permitted for the purposes of this study. The subject is currently participating in an investigational drug or another device study.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Denali inferior vena cava filter<br>All subjects enrolled will receive the Denali vena cava filter. | Device: Denali inferior vena cava filter<br>* The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.<br>* Other names: DL900F;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical Success of Placement | Technical success of filter placement is defined as the deployment of the filter such that the physician judges the location to be suitable to provide sufficient mechanical protection against Pulmonary Embolism. | 6 months | 
| Clinical Success of Placement | Is the one-sided lower limit of the 95% confidence interval for the observed clinical success rate at least 80%? Clinical success of filter placement is defined as freedom from subsequent Pulmonary Embolism (PE), filter embolization, caval occlusion, filter and procedure related death, insertion adverse events (AEs), and technical failure of placement. | 6 months | 
| Technical Success of Retrieval | Technical success for retrieval is defined as retrieval of the filter such that the entire filter is retrieved intact. | 24 months | 
| Clinical Success of Retrieval | Clinical success for retrieval is defined as successful technical retrieval of the filter without retrieval complications requiring intervention. Only the 121 successful retrievals are counted here. | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Recurring Pulmonary Embolism | Rate of recurrent Pulmonary Embolism while the filter is indwelling or one month post-retrieval. | 24 months | 
| Rate of New or Worsening Deep Vein Thrombosis | Rate of new or worsening Deep Vein Thrombosis (DVT) from placement to the six month follow-up. Worsening DVT is defined as an extension of existing DVT to a new venous segment on ultrasound in patients that had DVT at the baseline visit. | 6 months | 
| Filter Fracture | Rate of filter fracture | 6 months | 
| Filter Migration | Rate of filter indwell complications of: migration >2cm. | 6 months | 
| Filter Tilt at Placement | Rate of filter indwell complications of: tilt >15° | Post-placement imaging | 
| Filter Tilt at Retrieval | Rate of filter indwell complications of: tilt >15° | Pre-retrieval imaging | 
| Filter Penetration >3mm at Placement |  | Post-placement | 
| Filter Penetration >3mm at Retrieval |  | Pre-retrieval | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary embolism (PE), Deep vein thrombosis (DVT), Vena cava, Vena cava filter, Inferior vena cava, Venous thromboembolic disease (VTED)